OverviewChartProfileKey statisticsFinancialsTechnicalNews
Derivatives
TraderScreen

BioMarin Pharmaceutical Inc/  US09061G1013  /

NASDAQ
06/06/2024  22:00:00 Chg. +1.1800 Volume Bid10:07:19 Ask10:07:19 Market Capitalization Dividend Y. P/E Ratio
80.8500USD +1.48% 1.97 mill.
Turnover: 125.44 mill.		 73.1000Bid Size: 100 88.1000Ask Size: 100 15.35 bill.USD - 90.84
GlobeNewswire 05/06 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BridgeBio Pharma...
GlobeNewswire 28/05 Keros Therapeutics Appoints Jean-Jacques Bienaimé to its Board of Directors
GlobeNewswire 08/05 Terns Pharmaceuticals Announces Leadership Changes
GlobeNewswire 02/11/2023 California Life Sciences announces 20th annual Pantheon Award winners
GlobeNewswire 02/10/2023 California’s top scientific innovators selected as finalists for the 20th annual California Life Sci...
GlobeNewswire 01/03/2022 Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2021 Financial Results and Recent Corpor...
GlobeNewswire 14/02/2022 Vaxart Appoints Edward Berg as Senior Vice President and General Counsel
Newsfile Corp 04/02/2022 SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of BioMarin Pharmaceutical Inc.
GlobeNewswire 24/01/2022 SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of BioMarin Pharmaceutical Inc.
GlobeNewswire 23/12/2021 Lifshitz Law Firm, P.C. Announces Investigations of Amarin Corporation plc (NASDAQGM: AMRN), BioMari...
GlobeNewswire 21/12/2021 BMRN FINAL DEADLINE TOMORROW: ROSEN, NATIONAL TRIAL LAWYERS, Encourages BioMarin Pharmaceutical Inc....
GlobeNewswire 20/12/2021 BMRN & RECAF – Upcoming Lead Deadlines: Bronstein, Gewirtz & Grossman, LLC
GlobeNewswire 20/12/2021 SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in BioMar...
GlobeNewswire 17/12/2021 ROSEN, A LEADING LAW FIRM, Encourages BioMarin Pharmaceutical Inc. Investors with Losses to Secure C...
GlobeNewswire 07/12/2021 SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in BioMar...
GlobeNewswire 07/12/2021 ROSEN, A LEADING LAW FIRM, Encourages BioMarin Pharmaceutical Inc. Investors to Secure Counsel Befor...
GlobeNewswire 01/12/2021 SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in BioMar...
GlobeNewswire 30/11/2021 AMRN, BMRN & RECAF – Upcoming Class Actions Deadlines: Bronstein, Gewirtz & Grossman, LLC
GlobeNewswire 28/11/2021 ROSEN, A LEADING AND LONGSTANDING FIRM, Encourages BioMarin Pharmaceutical Inc. Investors with Losse...
GlobeNewswire 19/11/2021 AMRN, BMRN & RECAF – Class Actions Deadlines: Bronstein, Gewirtz & Grossman, LLC
GlobeNewswire 15/11/2021 Autolus Therapeutics announces the appointment of Dr. William D. Young as a Non-Executive Director
GlobeNewswire 13/11/2021 ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages BioMarin Pharmaceutical Inc. Investors with Lo...
GlobeNewswire 12/11/2021 AMRN, BMRN & RECAF – Class Action Alerts: Bronstein, Gewirtz & Grossman, LLC
GlobeNewswire 10/11/2021 INVESTOR REMINDER: BIOMARIN PHARMACEUTICAL INC. (NASDAQ: BMRN) SHAREHOLDER CLASS ACTION DEADLINE- Be...
GlobeNewswire 09/11/2021 SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in BioMar...